<DOC>
	<DOC>NCT01591850</DOC>
	<brief_summary>This randomized, single-center, open-label, one-sequence, two-period crossover study in three parts will assess the effects of multiple doses of ketoconazole, rifampicin and ritonavir-boosted atazanavir on the pharmacokinetics of a single dose of RO5093151 in healthy male and female volunteers. In Period 1, subjects will receive a single oral dose of RO5093151. In Period 2, subjects will receive a single oral dose of RO5093151 and multiple oral doses of either ketoconazole, rifampicin or ritonavir-boosted atazanavir. Anticipated time on study is up to 8.5 weeks.</brief_summary>
	<brief_title>A Drug-Drug Interaction Study of Ketoconazole, Rifampicin and Ritonavir-Boosted Atazanavir With Single-Dose RO5093151 in Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<mesh_term>Ketoconazole</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<criteria>Healthy male and female subjects, 18 to 65 years of age. Healthy status is defined by absence of evidence of any active or chronic disease following a detailed medical and surgical history and complete physical examination Body mass index (BMI) 18 to 30 kg/m2 Females of childbearing potential must agree to use two effective methods of contraception, including a barrier method and an intrauterine nonhormonal device (set in place at least 3 months before first dosing) for the duration of the study and at least 1 month after last dosing Nonsmoker for at least 90 days prior to screening Pregnant or lactating females History of drug abuse in the past 2 years, or suspicion of regular consumption of drugs of abuse, or positive result on drugs of abuse test History of alcoholism in the past 2 years, or positive alcohol test Positive for hepatitis B, hepatitis C or HIV infection Systemic , topical, intranasal or inhaled corticosteroid therapy for more than 2 weeks within 3 months prior to screening Participation in an investigational drug or device study within 90 days prior to screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>